Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA5A | P35218 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | PTPRA | P18433 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29246869 | 0.80 | DGAT1 (0.37) | DGAT1PTPRBCA2PTPN2PTPN1 | |
| SCHEMBL23539152 | 0.78 | DGAT1 (0.35) | DGAT1PTPRBCA2CA14CA12 | |
| SCHEMBL28438719 | 0.75 | NOS2 (0.31) | CA2CA1CA14CA7 | |
| SCHEMBL31531058 | 0.75 | ELANE (0.36) | — | |
| SCHEMBL31531056 | 0.75 | ELANE (0.36) | — | |
| SCHEMBL291019 | 0.72 | — | — | |
| SCHEMBL2022397 | 0.71 | DGAT1 (0.44) | DGAT1 | |
| SCHEMBL17574065 | 0.71 | DGAT1 (0.44) | DGAT1 | |
| Hydrochloric Acid SCHEMBL8906366 | 0.70 | KDM4E (0.39) | DGAT1 | |
| SCHEMBL1555747 | 0.70 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | SHIONOGI & CO., LTD. (JP) | 2021-06-22 | — | — | US | disclosed |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | SHIONOGI & CO., LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | DGAT1 1750/4885PTPRB 2015/4885CA2 1348/4885 |
| US-20200261481-A1 | A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG | RNASEH1, RNASEL, RNPEP | DGAT1 4390/4885PTPRB 2503/4885CA2 108/4885 |
| US-11040048-B2 | Medicament for treating influenza characterized by combining a Cap-dependent endonuclease inhibitor and an anti-influenza drug | RNASEH1, RNPEP, RNASEL | DGAT1 4402/4885PTPRB 2517/4885CA2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.